Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Saltikva + FOLFIRINOX
- Development stage
- Unknown
- Lead developer
- Salspera
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Oral, Intravenous
01
Overview
Saltikva + FOLFIRINOX is a combination regimen for treating advanced pancreatic cancer. It unites **Saltikva** (an orally administered, attenuated strain of *Salmonella typhimurium* genetically engineered to express human interleukin-2) with **FOLFIRINOX** (a chemotherapy protocol combining folinic acid, fluorouracil, irinotecan, and oxaliplatin). Saltikva acts primarily by stimulating immune-mediated antitumor activity in the tumor microenvironment through local delivery of IL-2, producing a surge in natural killer (NK) cell activity. FOLFIRINOX exerts cytotoxic antineoplastic effects via multiple mechanisms targeting DNA synthesis, cellular replication, and microtubule dynamics. In Phase 2 clinical studies in metastatic stage IV pancreatic cancer, this combination nearly doubled median overall survival over FOLFIRINOX alone, with no serious toxicities attributed to Saltikva.
- Other names
- Salmonella-IL2 + FOLFIRINOX
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)TUBB (Tubulin (alpha and beta subunits))TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on Saltikva + FOLFIRINOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Saltikva + FOLFIRINOX.